ShareValue scores for 6127.HK: Valuation 34, Quality 48, Growth 37, Health 65.

6127.HK
HKEX

Joinn Laboratories China Co Ltd

HK$23.76(-7.98%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

-6% to 9%
Valuation
34
Overvalued
Price vs Value
Quality
48
Moderate
Business Strength
Growth
37
Weak
Revenue & Earnings
Health
65
Moderate
Financial Stability
Momentum
97
Bullish
Price Trend

Company Details

About

Joinn Laboratories(China)Co.,Ltd. provides preclinical and non-clinical services in the United States, the People's Republic of China, and internationally. It operates through three segments: Non-Clinical Studies Services; Clinical Trial and Related Services; and Sales of Research Models. The Non-Clinical Studies Services segment offers drug safety assessment, drug metabolism and pharmacokinetics DMPK studies, and pharmacology and efficacy studies. Its Clinical Trial and Related Services segment provide clinical contract research organization services, co-managed phase I clinical research units, and bioanalytical services. The Sales of Research Models segment engages in the design, production, breeding, and sale of research models, including non-human primates and rodents. The company also offers cell-based assay (CBA) services. In addition, it offers drug quality research and testing services for protein drugs, vaccines, gene and cell therapy products, and provides customized solutions for early-stage drug discovery, screening, and mechanism research. Joinn Laboratories(China)Co.,Ltd. was incorporated in 1995 and is headquartered in Beijing, China.

Score Analysis

AI Investment Thesis

Data as of:Jul 20, 2026
|
Last calculated:Jul 20, 2026